Susceptibility and emm type of *Streptococcus pyogenes* isolated from children with severe infection

Hiroshi Sakata

**Abstract** Minimal inhibitory concentrations (MICs) and minimal bactericidal concentrations (MBCs) of various antimicrobial agents were measured against 12 strains of *Streptococcus pyogenes* isolated from children with invasive infections between 2003 and 2012. The patients ranged in age from 1 day to 15 years, with patients younger than 5 years, including three neonates, accounting for a half of the patients. The disease was sepsis in four patients, skin and soft tissue infection in three patients, retropharyngeal abscess in two patients, pneumonia plus sepsis in one patient, empyema in one patient, and pyogenic arthritis in one patient. One patient with sepsis died, while cure without sequelae was achieved in all the remaining patients. When classified by type, *emm*1 (six strains) was the most prevalent type, followed by *emm*12 (two strains). The MIC<sub>90</sub>/MBC<sub>90</sub> values were 0.015/0.015 µg/mL for penicillin G, 0.03/0.03 µg/mL for ampicillin, 0.015/0.03 µg/mL for cefotaxime, 0.03/0.03 µg/mL for ceftriaxone, 0.008/0.008 µg/mL for panipenem, 0.008/0.008 µg/mL for meropenem, and ≤0.004/≤0.004 µg/mL for doripenem, indicating the superior antimicrobial activities of carbapenem.

**Keywords** *Streptococcus pyogenes* · Susceptibility · *Emm* type · Bacteremia · Penicillin · Carbapenem

**Introduction** *Streptococcus pyogenes* is the major causative agent for pharyngitis and tonsillitis, but may also cause, although relatively rarely, invasive infections such as meningitis, sepsis, and necrotizing fasciitis. For such infections, treatment with antimicrobial agents exhibiting superior activity against *S. pyogenes* must be initiated immediately. Penicillin agents are representative drugs used as the agents of first choice for infections caused by hemolytic streptococci. However, many reports on the sensitivity of *S. pyogenes* to antimicrobial agents pertain to strains isolated from patients with pharyngitis or tonsillitis, and there are very few reports focusing on strains isolated from patients with invasive infections. Moreover, most of the drugs evaluated in comparison with the penicillins in these reports are oral antimicrobial agents, and there are no reports on the efficacy of intravenous antimicrobial agents, carbapenems in particular, used for the treatment of invasive infections.

In order to select appropriate antimicrobial agents for the treatment of hemolytic streptococcal infections associated with serious symptoms, the minimal inhibitory concentrations (MICs) and minimal bactericidal concentrations (MBCs) of various antimicrobial agents were examined for *S. pyogenes* strains isolated from children with invasive infections such as sepsis. Although many reports state that severe infection is associated with specific *emm* types, no results are available for children in Japan. Therefore, we evaluated this association.

**Subjects and method**

A total of 12 strains of *S. pyogenes* isolated from children who were examined for invasive infections at pediatric
departments in medical institutions in Hokkaido, including our hospital, during the 10-year period between July 2003 and June 2012 were included for this study. Severe infection with \textit{S. pyogenes} was defined as: (1) detection of \textit{S. pyogenes} from originally sterile sites such as blood, cerebrospinal fluid, and puncture fluid and (2) while \textit{S. pyogenes} was detected from non-sterile sites such as the skin and pharynx, no other bacteria could be assumed to be the cause and, furthermore, the pathology is not inconsistent with infection due to \textit{S. pyogenes}. Patients considered to have invasive infections were those with serious symptoms that were almost life-threatening, those requiring a surgical procedure such as drainage and/or debridement, and those requiring hospitalization for 2 weeks or more.

The MIC values of seven drugs (penicillin G, ampicillin, cefotaxime, ceftriaxone, panipenem, meropenem, doripenem) were measured by the broth microdilution method [1]. For determination of the MBC, a culture suspension of 10 μL was collected from the plate on which the MIC was measured and applied to non-selective culture media in wells containing the drug at a concentration equal to or greater than the MIC. After aerobic cultivation at 35°C for 20–24 h, the number of colonies were counted, and the concentration that caused a decrease in the volume of the growing bacteria by 99.9 % or more was determined as the MBC [2].

The Laboratory of Molecular Epidemiology for Infectious Agents, Kitasato Institute of Life Sciences, was requested to perform a determination of the \textit{emm} types. At the laboratory, M protein-coding genes were amplified by PCR and the base sequence at the 5' terminal end of the amplified product was determined; thereafter, that sequence of 300 bp was transmitted to the CDC Reference Center and the types were determined by matching with the CDC database [3].

Results

Table 1 shows a list of patients with invasive infections caused by \textit{S. pyogenes}. The patients ranged widely in age from 1 day to 15 years, with patients younger than 5 years, including three neonates, accounting for half of all the patients. None of the patients had any underlying diseases. The disease was sepsis in four patients, skin and soft tissue infection in three patients, retropharyngeal abscess in two patients, pneumonia plus sepsis in one patient, empyema in one patient, and pyogenic arthritis in one patient. None of the patients had concurrent toxic shock syndrome. One patient (a 15-year-old adolescent girl) with pneumonia plus sepsis died of shock. The most prevalent \textit{emm} type was \textit{emm}1 (six strains; 50.0 %), followed by \textit{emm}12 (two strains; 16.7 %), while \textit{emm}3, \textit{emm}4, \textit{emm}6, and \textit{emm}28 were recognized in one strain each.

Figures 1 and 2 show the distributions of the MICs and MBCs for each drug, and Table 2 shows the MIC$_{90}$ and MBC$_{90}$ values. The drug with the most potent antibacterial activity was doripenem, with MICs and MBCs of 0.004 μg/mL or less for all the strains. This drug was followed in antibacterial potency by panipenem, the MIC and MBC of which were determined to be 0.004 μg/mL and 0.008 μg/mL for six strains each. For meropenem, both the

\begin{table}[h]
\centering
\begin{tabular}{|c|c|c|c|c|c|}
\hline
Case number & Age & Type of \textit{emm} & Diagnosis & Isolated & Antibiotic therapy & Prognosis \\
\hline
1 & 1 day & 6 & Pyothorax & Pleural fluid & ABPC 11 days & Cure \\
2 & 4 days & 1 & Sepsis & Blood & ABPC 9 days & Cure \\
3 & 7 days & 1 & Sepsis & Blood & ABPC 11 days & Cure \\
4 & 1 year & 12 & Cellulitis & Skin swab & ABPC 7 days & Cure \\
5 & 3 years & 12 & Sepsis & Blood & ABPC 14 days & Cure \\
6 & 3 years & 1 & Sepsis & Blood & ABPC 14 days & Cure \\
7 & 5 years & 28 & Arthritis & Synovial fluid & CEZ 7 days & Cure \\
8$^a$ & 5 years & 4 & Retropharyngeal abscess & Pharyngeal swab & IPM/CS 2 days & Cure \\
9 & 7 years & 3 & Cellulitis & Skin exudate & IPM/CS 7 days & Cure \\
10 & 11 years & 1 & Erysipelas & Pharyngeal swab & ABPC 7 days & Cure \\
11 & 11 years & 1 & Retropharyngeal abscess & Pharyngeal swab & ABPC 10 days & Cure \\
12$^b$ & 15 years & 1 & Sepsis + pneumonia & Blood & PAPM/BP one shot & Dead \\
\hline
\end{tabular}
\caption{Characteristics of children with severe infection due to \textit{Streptococcus pyogenes}}
\end{table}

\textit{ABPC} ampicillin, \textit{CEZ} cefazolin, \textit{IPM/CS} imipenem/cilastatin sodium, \textit{PAPM/BP} panipenem/betamipron

$^a$ Patient was transferred to another hospital for operation

$^b$ Patient was transported in a state of shock in the evening by ambulance and was transferred to an advanced emergency medical care center after receiving basic life support and a single dose of PAPM/BP, but died the following morning. The patient had no underlying disease associated with increased susceptibility to infection
Fig. 1 Susceptibilities of *Streptococcus pyogenes* isolates to penicillins and cephems

Fig. 2 Susceptibilities of *S. pyogenes* isolates to carbapenems
Table 2 MIC and MBC of *S. pyogenes*

| Drug       | MIC range | MIC<sub>90</sub> | MBC range | MBC<sub>90</sub> |
|------------|-----------|------------------|-----------|------------------|
| Penicillin | 0.008 – 0.015 | 0.015            | 0.008 – 0.015 | 0.015            |
| Ampicillin | 0.015 – 0.03 | 0.03             | 0.015 – 0.03 | 0.03             |
| Cefotaxime | 0.015 – 0.03 | 0.015            | 0.015 – 0.03 | 0.03             |
| Ceftriaxone| 0.015 – 0.03 | 0.03             | 0.03 – 0.06  | 0.03             |
| Meropenem  | 0.008      | 0.008            | 0.008      | 0.008            |
| Panipenem  | ≤0.004 – 0.008 | 0.008         | ≤0.004 – 0.008 | 0.008         |
| Doripenem  | ≤0.004     | ≤0.004          | ≤0.004     | ≤0.004          |

MIC and MBC were 0.008 µg/mL for all strains. The drugs showing divergent values of the MIC and MBC were: penicillin G for five strains, ampicillin for three strains, cefotaxime for five strains, and ceftriaxone for eight strains. A comparison of the sensitivities to these four drugs revealed that penicillin G had the highest activity, followed by cefotaxime, ampicillin and ceftriaxone, in that order. There was no association between *emm* type and drug sensitivity.

**Discussion**

Invasive Group A streptococcal infections include sepsis, empyema, bone and joint infections, necrotizing fasciitis, and streptococcal toxic shock syndrome. According to a number of reports, the estimated incidence of invasive group A streptococcal infection in children in developed countries is 1–3 per 100,000 children, and the mortality is 5–20 % [4]. While among all age groups, the incidence is the highest in elderly people, children younger than 5 years of age are the next most commonly affected age group [5].

Among reports on invasive group A streptococcal infections in children, Mulla [6] from the United States reported the outcomes of 25 children ranging in age from 3 weeks to 17 years with hemolytic streptococcal infections, who were examined between 1996 and 2000. In regard to the patients’ age, six children were younger than 1 year old and eight children were 1–4 years of age, with children younger than 5 years accounting for more than half of the cases. With regard to the presence of invasive disease, 18 patients had bacteremia and three had necrotizing fasciitis. The mortality was 4.4 %. Henriet et al. [7] from France reported that, among 28 children examined between 2000 and 2007, 15 had joint infections, seven had soft tissue infections, three had pneumonia, and three had toxic shock syndrome, and the median age was 2.9 years.

Wajima et al. [3] analyzed the *emm* types of *S. pyogenes* isolated from patients with invasive group A streptococcal infections diagnosed at medical institutions in Japan between 2003 and 2006. Among the 74 strains obtained, many were isolated from patients aged 60–80 years, while only 11 strains (14.9 %) were isolated from patients younger than 20 years of age. Among the 74 strains, the most prevalent type was *emm1* (29 strains; 39.2 %), followed by *emm49* (eight strains; 10.8 %) and *emm12* and *emm28* (five strains each; 6.7 %). The *emm1* type was the most prevalent, which was consistent with the results of the present study. In regard to results reported from Europe and the United States, according to one report, out of 247 strains, including those isolated from pediatric patients in Spain between 1998 and 2009, the most prevalent *emm* type was *emm1* (60 strains; 24.3 %), followed by *emm3* (21 strains; 8.5 %) and *emm4* (14 strains; 5.7 %); these results indicate a high prevalence of the *emm1* type [8]. In Germany, evaluation of 586 strains revealed that the most prevalent *emm* type was *emm1* (179 strains; 30.5 %), accounting for nearly one-third of all the strains, followed by *emm28* (107 strains; 18.3 %) and *emm3* (56 strains; 9.6 %) [9]. Similarly, *emm1* was also the most commonly identified type according to other reports, indicating that invasive infections are strongly associated with the *emm1* type [7,10]. According to recent studies [11,12], *emm12* is the most common among the *emm* types of *S. pyogenes* isolated from pharyngitis. However, the frequencies of *emm1* were about half of those in severe infections, showing differences in distributions of *emm* types between pharyngitis and severe infections.

While there are many reports [7,9,13,14] examining the associations between *emm* types and pathogenic factors, such as toxin production and super-antigens, why *emm* type 1 is commonly detected in severe infections has not been elucidated.

Among the drugs used in the drug sensitivity testing, doripenem exhibited the highest activity, with an MIC of 0.004 µg/mL against all strains. The MIC<sub>90</sub> values of panipenem and meropenem were 0.008 µg/mL, indicating the superior antibacterial activity of these drugs as compared to that of other agents (MIC<sub>90</sub>: 0.015–0.03 µg/mL). The MIC and MBC of carbapenem agents were consistent for all strains, whereas those of the penicillin agents and cepham agents were not quite so consistent. No reports have focused on *S. pyogenes* exhibiting resistance to penicillin agents, although there are occasional reports of tolerance [15–17]; it is considered that, due to the divergence between MIC and MBC, the strain requires more time to be killed as compared to other strains, or there is some kind of mechanism against killing in the bacteria. This phenomenon is considered to be one of the reasons for the recurrence of pharyngitis and tonsillitis caused by *S. pyogenes*, even after the administration of effective antimicrobial agents [18,19]. Moreover, it is also considered to be one reason why not a few patients treated with penicillin alone have poor outcomes in association with the “inoeculum
treatment of severe infection. It is thus considered to be appropriate for the raising the possibility of high efficacy in the early stage, but further basic and clinical investigations on other study comparing the sensitivities of S. pyogenes, however, this phenomenon seems to require attention. 

Penicillin agents are considered as the drugs of first choice for invasive streptococcal infections, and concurrent use of clindamycin is recommended, with the expectation of its special antimicrobial activities, such as tissue permeability, inhibition of toxin production, and promotion of phagocytic activity. Carbapenem agents have lower MBC than penicillin agents and, moreover, penicillin is highly effective in the log phase while its effect decreases in a steady state. However, there are results, albeit in vitro, raising the possibility of high efficacy in the early stationary phase. It is thus considered to be appropriate for the treatment of severe S. pyogenes infection. As there is no other study comparing the sensitivities of S. pyogenes to penicillin agents, carbapenem agents, and cephem agents, this awaits further basic and clinical investigations.

Acknowledgments I deeply thank Prof. Kimiko Ubukata and co-workers at the Laboratory of Molecular Epidemiology for Infectious Agents, Kitasato Institute for Life Science, Kitasato University, for analysis of the emm type of S. pyogenes. This work was supported by grants for a ‘Research Project for Emerging and Re-emerging Infectious Diseases’ (H-22-013) from the Japanese Ministry of Health, Labour and Welfare.

Conflict of interest None.

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

1. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. Approved Standard M07-A8. 8th ed. Wayne: CLSI; 2009.
2. National Committee for Clinical Laboratory Standards. Methods for determining bactericidal activity of antimicrobial agents; Approved guideline. M26-A. Wayne: NCCLS; 1999.
3. Wajima T, Murayama SY, Sunaoshi K, Nakayama E, Sunakawa K, Ubukata K. Distribution of emm type and antibiotic susceptibility of group A streptococci causing invasive and noninvasive disease. J Med Microbiol. 2008;57:1383–8.
4. Steer AC, Lamagni T, Curtis N, Carapetis JR. Invasive group A streptococcal disease: epidemiology, pathogenesis and management. Drugs. 2012;72:1213–27.
5. Steer AC, Jenney A, Kado J, Good MF, Batzloff M, Waqatakirewa L, et al. Prospective surveillance of invasive group a streptococcal disease, Fiji. 2005–2007. Emerg Infect Dis. 2009;15:216–22.
6. Mulla ZD. Clinical and epidemiologic features of invasive group A streptococcal infections in children. Pediatr Int. 2007;49:358–5.
7. Henriet S, Kaguelidou F, Bidet P, Lorrot M, De Lauzanne A, Dauger S, et al. Invasive group A streptococcal infection in children: clinical manifestations and molecular characterization in a French pediatric tertiary care center. Eur J Clin Microbiol Infect Dis. 2010;29:341–6.
8. Montes M, Ardanuy C, Tamayo E, Domenech A, Liñares J, Pérez-Trallero E. Epidemiological and molecular analysis of Streptococcus pyogenes isolates causing invasive disease in Spain (1998–2009): comparison with non-invasive isolates. Eur J Clin Microbiol Infect Dis. 2011;30:1295–302.
9. Imöhl M, Reintert RR, Ockelkrag C, van der Linden M. Epidemiology of invasive Streptococcus pyogenes disease in Germany during 2003–2007. FEMS Immunol Med Microbiol. 2010;58:389–96.
10. Giljander T, Lyytikäinen O, Vähiäkuppus S, Snellman M, Jalava J, Vuopio J. Epidemiology, outcome and emm types of invasive group A streptococcal infections in Finland. Eur J Clin Microbiol Infect Dis. 2010;29:1299–35.
11. Shulman ST, Tanaz RR, Kabat W, Kabat K, Cederlund E, Patel D, et al. Group A streptococcal pharyngitis serotype surveillance in North America, 2000–2002. Clinic Infect Dis. 2004;39:525–32.
12. Shea PR, Ewbank AL, Gonzalez-Lugo JH, Martagon-Rosado AJ, Martinez-Gutierrez JC, Rehman HA, et al. Group A Streptococcus emm gene types in pharyngeal isolates. Ontario, Canada. 2002–2010. Emerg Infect Dis. 2011;17:2010–7.
13. Chatellier S, Ihendyane N, Kansal RG, Khambaty F, Basma H, Norrbry-Teplund A, et al. Genetic relatedness and superantigen expression in group A streptococcal serotype M1 isolates from patients with severe and nonsevere invasive diseases. Infect Immun. 2000;68:3523–34.
14. Liang Y, Liu X, Chang H, Ji L, Huang G, Fu Z, et al. Epidemiological and molecular characteristics of clinical isolates of Streptococcus pyogenes collected between 2005 and 2008 from Chinese children. J Med Microbiol. 2012;61(Pt 7):975–83.
15. Krasinski K, Hanna B, LaRuspa P, Desiderio D. Penicillin tolerant group A streptococci. Diagn Microbiol Infect Dis. 1986;4:291–7.
16. Van Asselt GJ, Van Boven CP. Guidelines for detection of penicillin tolerance in Streptococcus pyogenes. Clin Microbiol Infect. 2000;6:503–8.
17. Steininger C, Allerberger F, Gnaiger E. Clinical significance of inhibition kinetics for Streptococcus pyogenes in response to penicillin. J Antimicrob Chemother. 2002;50:517–23.
18. Kim KS, Kaplan EL. Association of penicillin tolerance with failure to eradicate group A streptococci from patients with pharyngitis. J Pediatr. 1985;107(5):681–4.
19. Dagan R, Ferme N. Association of penicillin-tolerant streptococci with epidemics of streptococcal pharyngitis in closed communities. Eur J Clin Microbiol Infect Dis. 2010;29:1229–35.
20. Eagle H. Experimental approach to the problem of treatment failure with penicillin. I. Group A streptococcal infection in mice. Am J Med. 1952;13:389–99.
21. EUCAST Definitive Document E. Def 1.2, May 2000: Terminology relating to methods for the determination of susceptibility of bacteria to antimicrobial agents. European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESC-MID). Clin Microbiol Infect 2000;6:503–8.
22. Nishino T, Otsuki M, Izawa M. In vivo and in vitro antibacterial activity of doripenem. Jpn J Chemotherapy. 2005;53(1):32–46.